Exagen (XGN) Current Deferred Revenue (2024 - 2026)

Exagen (XGN) has 3 years of Current Deferred Revenue data on file, last reported at $681000.0 in Q1 2026.

• Quarterly Current Deferred Revenue fell 24.33% year-over-year to $681000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $681000.0 (down 24.33% YoY) and the FY2025 annual result came in at $675000.0, down 7.91% from the prior year.
• Current Deferred Revenue climbed to $681000.0 in Q1 2026, from $675000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $1.0 million in Q2 2025 to a low of $600000.0 in Q3 2025.
• A 3-year average of $764833.3 and a median of $707000.0 in 2024 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2025 — Current Deferred Revenue retreated 7.91% — and 2026, when it retreated 24.33%.
• Tracing XGN's Current Deferred Revenue over 3 years: stood at $733000.0 in 2024, then declined by 7.91% to $675000.0 in 2025, then increased by 0.89% to $681000.0 in 2026.
• The last three Current Deferred Revenue figures came in at $681000.0 (Q1 2026), $675000.0 (Q4 2025), and $600000.0 (Q3 2025), per Business Quant data.